急性卒中再灌注试验中影像生物标志物的患病率
本研究纳入612例症状出现24小时内的疑似急性缺血性卒中患者,回顾性分析基线CT、灌注CT和CTA影像生物标志物在不同时间窗的患病率。结果显示多数连续影像特征随时间变化,部分二分类特征(如ASPECT评分、致密动脉征、梗死体积、侧支评分和可见血栓)显著依赖时间,而阈值化灌注CT半暗带体积不随时间显著变化。该分析有助于试验设计时确定样本量和需筛查人数。
要点
- 常用影像生物标志物患病率随时间窗变化,影响试验筛选。
- ASPECT评分、致密动脉征、梗死体积、侧支评分和可见血栓显著依赖时间。
- 阈值化灌注CT半暗带体积不随时间显著变化,或可稳定用于筛选。
核心结论
- 影像生物标志物患病率随时间变化,分析表格可辅助卒中临床试验的可行性分析和样本量估算。
研究设计与样本
- 回顾性研究纳入612例症状出现24小时内完成基线影像的疑似急性缺血性卒中患者,排除亚急性/慢性/陈旧梗死和出血。
主要发现
- 所有连续影像特征随时间变化。
- 二分类特征中,非增强CT的ASPECT评分和致密动脉征、灌注CT梗死体积、CTA侧支评分和可见血栓随时间显著变化。
- 阈值化灌注CT半暗带体积不随时间显著变化。
关键数值与推荐
- 研究创建了不同时间窗下核心梗死、半暗带和动脉闭塞相关影像生物标志物的患病率表格。
临床怎么用
- 研究者可利用这些表格确定样本量和需筛查人数,优化以影像生物标志物为筛选标准的卒中试验设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Imaging biomarkers are increasingly used as selection criteria for stroke clinical trials. The goal of our study was to determine the prevalence of commonly studied imaging biomarkers in different time windows after acute ischemic stroke onset to better facilitate the design of stroke clinical trials using such biomarkers for patient selection. METHODS: This retrospective study included 612 patients admitted with a clinical suspicion of acute ischemic stroke with symptom onset no more than 24 hours before completing baseline imaging. Patients with subacute/chronic/remote infarcts and hemorrhage were excluded from this study. Imaging biomarkers were extracted from baseline imaging, which included a noncontrast head computed tomography (CT), perfusion CT, and CT angiography. The prevalence of dichotomized versions of each of the imaging biomarkers in several time windows (time since symptom onset) was assessed and statistically modeled to assess time dependence (not lack thereof). RESULTS: We created tables showing the prevalence of the imaging biomarkers pertaining to the core, the penumbra and the arterial occlusion for different time windows. All continuous imaging features vary over time. The dichotomized imaging features that vary significantly over time include: noncontrast head computed tomography Alberta Stroke Program Early CT (ASPECT) score and dense artery sign, perfusion CT infarct volume, and CT angiography collateral score and visible clot. The dichotomized imaging features that did not vary significantly over time include the thresholded perfusion CT penumbra volumes. CONCLUSIONS: As part of the feasibility analysis in stroke clinical trials, this analysis and the resulting tables can help investigators determine sample size and the number needed to screen.
引用
- Jiang B, Ball RL, Michel P, et al. Prevalence of Imaging Biomarkers to Guide the Planning of Acute Stroke Reperfusion Trials. Stroke. 2017. PMID: 28386041. doi:10.1161/STROKEAHA.117.016759
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。